癌症免疫治疗市场规模- 分产品（单株抗体、癌症疫苗、免疫调节剂、溶瘤病毒疗法、细胞激素）、癌症类型（肺癌、乳癌、大肠癌、摄护腺癌、胰臟癌）、最终用途和预测，2024 - 2032 年

由于癌症发生率不断上升，2024 年至 2032 年间，全球癌症免疫治疗市场的复合年增长率将超过 9.3%，从而增强了对先进有效治疗方案的需求。

免疫疗法利用人体的免疫系统来瞄准并摧毁癌细胞，为传统疗法提供了一个有前景的替代方案。生物技术和分子医学的进步促进了创新免疫疗法药物的开发，与传统治疗方法相比，这些药物具有更高的疗效和更少的副作用。此外，製药公司对研发的大量投资和有利的监管政策正在加速新免疫疗法产品的批准和商业化。例如，2024年6月，FDA批准默沙东的KEYTRUDA(R) pembrolizumab合併卡铂和紫杉醇治疗晚期或復发性子宫内膜癌。

癌症免疫治疗市场根据产品、癌症类型、最终用途和地区进行细分。

由于对个人化医疗的日益重视以及对能够有效调节免疫系统的疗法的需求，免疫调节剂领域将在 2032 年呈现出值得注意的复合年增长率。免疫调节剂可增强人体对癌症的天然防御能力，进而产生更量身订做且可能有效的治疗方案。此外，随着研究揭示癌症与免疫系统之间复杂的相互作用，人们更加关注开发专门针对这些机制的疗法。这种不断增长的理解以及对更精确和适应性治疗的追求猛增了对免疫调节剂的需求。

受未满足的医疗需求和疾病的复杂性的推动，到 2032 年，肺癌领域将占据前景广阔的癌症免疫治疗市场份额。肺癌死亡率高且亚型多样，对有效治疗提出了重大挑战。免疫疗法透过针对特定癌细胞并有可能改善患者的治疗结果，提供了一种有前景的替代方案。针对肺癌创新治疗的持续研发工作将推动该领域的成长。

北美癌症免疫治疗市场在预测期内将呈现出有希望的复合年增长率。先进的医疗基础设施和高水准的研究经费促进了新疗法的快速开发和采用。该地区成熟的製药和生物技术产业有助于快速创新和监管批准。此外，公共和私人对癌症研究的投资不断增加，加上癌症发生率的上升，增加了对有效治疗的需求。对个人化医疗和患者获得现代疗法的高度重视将刺激整个地区采用免疫疗法解决方案。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业影响力
  • 成长动力
    • 癌症盛行率上升
    • 研究与开发的进步
    • 个性化医疗和生物标誌开发
  • 产业陷阱与挑战
    • 治疗费用高
    • 与治疗相关的副作用风险
• 成长潜力分析
• 技术景观
• 监管环境
• 波特的分析
• PESTEL分析

第 4 章：竞争格局

• 介绍
• 公司市占率分析
• 竞争定位矩阵
• 战略展望矩阵

第 5 章：市场估计与预测：按产品分类，2021 - 2032 年

• 主要趋势
• 单株抗体
• 癌症疫苗
• 免疫调节剂
  • 检查点抑制剂
  • 免疫检查点调节剂
  • 其他免疫调节剂
• 细胞因子
• 溶瘤病毒疗法

第 6 章：市场估计与预测：按癌症类型，2021 - 2032 年

• 主要趋势
• 肺癌
• 乳癌
• 大肠直肠癌
• 黑色素瘤
• 摄护腺癌
• 胰腺癌
• 其他癌症类型

第 7 章：市场估计与预测：按最终用途，2021 - 2032 年

• 主要趋势
• 医院
• 专科诊所
• 癌症研究中心

第 8 章：市场估计与预测：按地区，2021 - 2032

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
  • 欧洲其他地区
• 亚太地区
  • 日本
  • 中国
  • 印度
  • 澳洲
  • 韩国
  • 亚太地区其他地区
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 拉丁美洲其他地区
• 中东和非洲
  • 沙乌地阿拉伯
  • 南非
  • 阿联酋
  • 中东和非洲其他地区

第 9 章：公司简介

• AbbVie Inc.
• Amgen Inc.
• AstraZeneca PLC
• Bayer AG
• Bristol-Myers Squibb Company
• Celldex Therapeutics, Inc.
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd.
• Gilead Sciences, Inc.
• GSK plc
• Immunocore Holdings plc
• Johnson & Johnson
• Merck & Co., Inc
• Novartis AG
• Pfizer Inc.

Global Cancer Immunotherapy Market will witness over 9.3% CAGR between 2024 and 2032, catapulted by the escalating cancer incidence, bolstering the demand for advanced and effective treatment options.

Immunotherapy, which harnesses the body's immune system to target and destroy cancer cells, offers a promising alternative to traditional treatments. Advancements in biotechnology and molecular medicine have led to the development of innovative immunotherapy drugs that offer improved efficacy and fewer side effects compared to traditional treatments. Additionally, substantial investments in R&D by pharmaceutical companies and favorable regulatory policies are accelerating the approval and commercialization of new immunotherapy products. For instance, in June 2024, the FDA approved Merck's KEYTRUDA(R) pembrolizumab combined with carboplatin and paclitaxel as treatment for advanced or recurrent endometrial carcinoma.

The cancer immunotherapy market is segmented based on product, cancer type, end-use, and region.

The immunomodulators segment will showcase a noteworthy CAGR through 2032, due to a growing emphasis on personalized medicine and the need for therapies that can modulate the immune system effectively. Immunomodulators enhance the body's natural defenses against cancer, leading to more tailored and potentially effective treatment options. Additionally, as research reveals the complex interactions between cancer and the immune system, there is a heightened focus on developing therapies that can specifically target these mechanisms. This growing understanding and the quest for more precise and adaptive treatments catapult the demand for immunomodulators.

The lung cancer segment will hold a promising cancer immunotherapy market share by 2032, driven by the high unmet medical need and the complex nature of the disease. Lung cancer, with its high mortality rate and diverse subtypes, presents significant challenges for effective treatment. Immunotherapy offers a promising alternative by targeting specific cancer cells and potentially improving patient outcomes. The continued R&D efforts aimed at innovative treatments for lung cancer will drive the segment growth.

North America cancer immunotherapy market will exhibit a promising CAGR during the forecast period. Advanced healthcare infrastructure and high levels of research funding facilitate rapid development and adoption of new therapies. The regions well-established pharmaceutical and biotech industries contribute to swift innovation and regulatory approvals. Additionally, increasing public and private investments in cancer research, coupled with a rising prevalence of cancer cases, heighten the demand for effective treatments. The strong emphasis on personalized medicine and patient access to modern therapies will spur the adoption of immunotherapy solutions across the region.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360°synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of cancer
    • 3.2.1.2 Advancements in research and development
    • 3.2.1.3 Personalized medicine and biomarker development
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 High treatment costs
    • 3.2.2.2 Risk of side effects associated with the treatment
• 3.3 Growth potential analysis
• 3.4 Technological landscape
• 3.5 Regulatory landscape
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Competitive positioning matrix
• 4.4 Strategy outlook matrix

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Monoclonal antibodies
• 5.3 Cancer vaccines
• 5.4 Immunomodulators
  • 5.4.1 Checkpoint inhibitors
  • 5.4.2 Immune checkpoint modulators
  • 5.4.3 Other immunomodulators
• 5.5 Cytokines
• 5.6 Oncolytic viral therapies

Chapter 6 Market Estimates and Forecast, By Cancer Type, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Lung cancer
• 6.3 Breast cancer
• 6.4 Colorectal cancer
• 6.5 Melanoma
• 6.6 Prostate cancer
• 6.7 Pancreatic cancer
• 6.8 Other cancer types

Chapter 7 Market Estimates and Forecast, By End-Use, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Hospitals
• 7.3 Specialty clinics
• 7.4 Cancer research centers

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
  • 8.3.7 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 Japan
  • 8.4.2 China
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
  • 8.5.4 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 Saudi Arabia
  • 8.6.2 South Africa
  • 8.6.3 UAE
  • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 AbbVie Inc.
• 9.2 Amgen Inc.
• 9.3 AstraZeneca PLC
• 9.4 Bayer AG
• 9.5 Bristol-Myers Squibb Company
• 9.6 Celldex Therapeutics, Inc.
• 9.7 Eli Lilly and Company
• 9.8 F. Hoffmann-La Roche Ltd.
• 9.9 Gilead Sciences, Inc.
• 9.10 GSK plc
• 9.11 Immunocore Holdings plc
• 9.12 Johnson & Johnson
• 9.13 Merck & Co., Inc
• 9.14 Novartis AG
• 9.15 Pfizer Inc.